Publication date: Jul 18, 2025
The COVID-19 pandemic accelerated vaccine development and generated a rapidly evolving body of evidence before and after the vaccine rollout. We developed a robust online platform to efficiently synthesize this emerging information for current and future challenges. Expanding upon our interactive living systematic review-initially focused on COVID-19- we now include chikungunya and Lassa fever (with protocols presented in this issue), Mpox, and Disease X ( https://www. safeinpregnancy. org ). We aim to continuously monitor and periodically update and disseminate high-quality data on vaccine safety, efficacy, effectiveness, and immunogenicity in pregnancy and childhood. This platform computes real-time meta-analyses and features a visualization tool to present findings in a clear and accessible manner, supporting decision-making, vaccine development pipelines, and implementation strategies worldwide. It is also designed to integrate data on a hub of emerging vaccines in pregnancy and childhood and reflects a collaborative effort among multiple organizations.
| Concepts | Keywords |
|---|---|
| Covid | Child |
| Global | COVID-19 |
| Periodically | COVID-19 Vaccines |
| Safeinpregnancy | COVID-19 Vaccines |
| Vaccines | Female |
| Humans | |
| Meta-Analysis as Topic | |
| Pregnancy | |
| SARS-CoV-2 | |
| Vaccine Development |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Huperzine B |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | Lassa fever |
| disease | IDO | quality |